Human TNF-α Antibody - Adalimumab IgA2 Isotype

Human IgA2

ABOUT

TNF-alpha Antagonist - Human IgA2 (low effector functions)

Anti-hTNF-α-hIgA2 is an adalimumab-based research antibody. Adalimumab (ABBV-3373, HY-P9908) is a fully human IgG1κ monoclonal antibody that specifically binds human tumor necrosis factor alpha (TNF-α). It blocks the interaction of soluble and membrane-bound TNF-α with the TNF receptors (TNFR1 and TNFR2) and thereby inhibiting TNF-α-mediated inflammatory signaling. Adalimumab is FDA-approved for the treatment of multiple chronic inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, juvenile idiopathic arthritis, and non-infectious uveitis.

More details More details

 

Anti-hTNF-α-hIgA2 comprises the variable region of Adalimumab and a human IgA2 constant region for low effector functions. For applications requiring high Fc effector activity, InvivoGen also offer Anti-hTNF-α-hIgG1, the biosimilar research antibody to Adalimumab.

This mAb is suitable for neutralization assays, screening assays, and studies of TNF-α signaling. It effectively neutralizes the biological activity of recombinant human TNF-α in vitro, as tested using HEK-Blue™ TNF-α cells (see figure).
 

Key features

  • Each lot is functionally tested and validated
  • The complete sequence of the antibody construct has been verified
  • Absence of endotoxins determined by the EndotoxDetect assay

 

More isotypes of this antibody are available and can be used for comparison of biological activities such as ADCC (see in the 'upon request' section). 

Review Learn more about antibody isotype effector functions by reading our flyer on Clinically relevant monoclonal antibodies.

All products are for research use only, and not for human or veterinary use.

Binding of anti-TNF-α mAb
Binding of anti-TNF-α mAb

SPECIFICATIONS

Specifications

Target

TNF-α

Target species

Human

Antibody applications
Neutralization assay
Species
Human
Isotype
hIgA2
kappa
Clone
Adalimumab
Tag
Tag-free
Source
CHO cells
Purification
Protein A
Formulation buffer

Sodium phosphate buffer, glycine, saccharose, stabilizing agents

Preservative
Azide-free
Purity
≥ 95 %
Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Endotoxin

Negative (tested using EndotoxDetect™ assay)

Tested applications

Neutralization assay

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hTNF-α-hIgA2
  • Cat code: 
    htnfa-mab7
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Tumor necrosis factor-alpha (TNF-α) is a pleiotropic cytokine involved in necrotic and apoptotic cell death, cellular differentiation, inflammation, and regulation of immune cell activity [1]. Notably, deregulated TNF-α production has been implicated in a variety of conditions, including autoimmune and inflammatory diseases [1]. TNF-α is mainly produced by activated monocytes, macrophages, and T cells. It is first synthesized as a membrane-bound molecule (tmTNF) that forms a compact homotrimer through non-covalent interactions. The trimeric membrane-bound form is cleaved by tumor necrosis factor-alpha converting enzyme (TACE) releasing the soluble trimer (sTNF) [2].

Both the membrane-bound and soluble TNF-α bind homotrimeric transmembrane receptors, TNFR1 or TNFR2, triggering signaling pathways that involve TRADD, TRAF2, and RIP, and leading to the activation of NF-κB and MAPK pathways [2]. Importantly, membrane-bound TNF can also mediate a reverse "outside-to-inside" signaling, although this mechanism remains to be fully elucidated [2]. 

Adalimumab is a therapeutic, fully human IgG1 monoclonal antibody (mAb) that targets and blocks the interaction of both tmTNF-α and sTNF-α with TNFR1 and TNFR2, thereby downregulating the inflammatory responses. Adalimumab is used in the treatment of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis [3].

 

References:

1. Steeland S., et al. 2018. A new venue of TNF targeting. Int. J. Mol. Sci. 19:1442.
2. Shealy D.J. & Visvanathan S. 2008. Anti-TNF antibodies: lessons from the past, roadmap for the future. Therapeutic Antibodies (book). 101-129.
3. FDA website, visited Dec 2024: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s410lbl.pdf

 

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?